Rs 800 crore projects launched in Hyderabad's Genome Valley

Image
IANS Hyderabad
Last Updated : Sep 06 2018 | 9:40 PM IST

Telangana's Minister of Industries K.T. Rama Rao on Thursday inaugurated new projects worth Rs 800 crore in Genome Valley here.

The new projects include biosimilars manufacturing, advanced pharma and biotech R&D, formulation manufacturing and integrated turnkey lab spaces for high-tech research.

These projects of varied nature signify the large breadth of capabilities present in Genome Valley, which has emerged as Asia's largest high innovation and life sciences cluster, according to an official release.

The Hyderabad-based GeneSys Biologics, a specialty biotech company engaged in R&D of advanced biosimilars, announced the inauguration of their state-of-the-art biotechnology manufacturing facility in Genome Valley.

GeneSys plans to deploy around Rs 350 crores overall in their facility which will see a 10 to 20 fold increase in their output and lead to large scale direct employment opportunities for highly skilled workforce.

"Given the extraordinary strengths of Telangana in vaccines and pharmaceuticals, we have taken various initiatives focussed on accelerating biologics and biosimilars development as part of the Genome Valley 2.0 Vision," said the minister.

In another major boost to the Genome Valley cluster, the fastest growing Canadian generic drug manufacturer JAMP Pharma will be setting up its biggest center of excellence for R&D and manufacturing of export quality drug formulations and will invest around Rs 250 crores with generation of 2,000 direct jobs over the next 24 months.

Monsieur Louis Pilon, Global President and CEO of Jamp Pharma Corp, met the Minister, who assured him of complete support of the state authorities and requested him to consider scaling up Jamp Pharma's operations in Hyderabad.

Laxai Life Sciences, a Genome Valley based custom biotech and pharma R&D, also inaugurated its new 50,000 square feet facility in Genome Valley with state-of-the-art German R&D infrastructure, which will cater to development of novel small molecules, biologics and custom pharma services for US and European companies.

Foundation stone was also laid for Touchstone Square, an integrated and collaborative R&D park through proposed investment of Rs 150 crore.

--IANS

ms/mr

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 06 2018 | 9:32 PM IST

Next Story